|
The European Bioanalysis Forum (EBF) is an organisation comprising bioanalytical scientists working within the pharmaceutical industry R&D. Scope of the EBF is on bioanalysis of small and large molecules with ''bioanalysis'' being defined as: * Quantification of drugs and metabolites in body fluids and tissues * Quantification of PD and safety biomarkers amenable to conventional bioanalytical techniques * Bioanalytical characterization of NBEs Members discuss on regulatory issues and aspects (new guidelines, interpretation of existing guidelines) and present their joint opinion towards regulatory bodies and their peers. Further, they share common practices on procedures, science, Laboratory Information Management Systems (LIMS), validation, quality (GLP) and discuss new developments in industry. ==History== The EBF was founded in the fall of 2006 at the initiative of twelve pharmaceutical companies, all of them having bioanalytical laboratory activities in Europe. The goal of bringing these companies together was to implement a platform for discussions of science and regulatory issues. Views and recommendations following from these discussions are either published in scientific journals, like for example on the controversial and much debated topic of incurred sample reproducibility or presented at international meetings. As of May 2010 the EBF consists of 28 member companies. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「European Bioanalysis Forum」の詳細全文を読む スポンサード リンク
|